Medical News Today: All you need to know about metoprolol
Metoprolol is a beta-blocker that doctors often prescribe to treat cardiovascular issues, such as high blood pressure and angina. Different types of metoprolol have different uses. Learn more about how this drug works, when a doctor may prescribe it, and what the potential side effects can be here. (Source: Health News from Medical News Today)
Source: Health News from Medical News Today - December 18, 2018 Category: Consumer Health News Tags: Pharmacy / Pharmacist Source Type: news
PCI in Cancer; Beta-Blocker Prophylaxis; Stress Echo Predicts Cancer Deaths
(MedPage Today) -- Updates on the latest advances in cardio-oncology (Source: MedPage Today Cardiovascular)
Source: MedPage Today Cardiovascular - December 10, 2018 Category: Cardiology Source Type: news
Flu jab is a lifesaver for heart failure patients
Researchers from the University of Copenhagen, led by cardiologist Dr Daniel Modin, urge for the flu jab to become part of the standard treatment for heart failure, like beta blockers. (Source: the Mail online | Health)
Source: the Mail online | Health - December 10, 2018 Category: Consumer Health News Source Type: news
Effect of preadmission beta-blockade on mortality in multiple trauma - Eriksson M, von Oelreich E, Brattstr öm O, Eriksson J, Larsson E, Oldner A.
BACKGROUND: High levels of circulating catecholamines after multiple trauma have been associated with increased morbidity and mortality. Beta-adrenergic receptor antagonist (beta-blocker) therapy has emerged as a potential treatment option, but the effect ... (Source: SafetyLit)
Source: SafetyLit - December 6, 2018 Category: International Medicine & Public Health Tags: Economics of Injury and Safety, PTSD, Injury Outcomes Source Type: news
Resumption of Beta-Blockers After Noncardiothoracic Surgery Resumption of Beta-Blockers After Noncardiothoracic Surgery
For patients taking long-term beta-blockers, what is the optimal timing for resumption following noncardiac surgery?Anesthesiology (Source: Medscape Today Headlines)
Source: Medscape Today Headlines - November 29, 2018 Category: Consumer Health News Tags: General Surgery Journal Article Source Type: news
BioCardia Developing Comprehensive Approach to Treat Heart Failure
It can be a bit trick when trying to put BioCardia’s cell therapy for heart failure in one specific category. Is the CardiAmp Cell Therapy a diagnostic, device, or a biologic? Perhaps it’s all of the above. The San Carlos, CA-based company’s president and CEO painted a clearer picture for the technology noting that it could play a significant role when looking at heart failure treatment.
“The [CardiAMP Cell Therapy System] is regulated by the agency [FDA] as a combination product via an IDE PMA device pathway,†Peter Altman, BioCardia...
Source: MDDI - November 16, 2018 Category: Medical Devices Authors: Omar Ford Tags: Cardiovascular Business Source Type: news
Another Chance for Medtronic ’s Renal Denervation Therapy
Medtronic has yet another chance to prove its renal denervation therapy can treat uncontrolled hypertension. The Dublin-based company has received FDA approval to begin a clinical trial to evaluate the Symplicity Spyral renal denervation system with patients on medication for high blood pressure.
The ON MED Trial is a 2:1 randomized, sham-controlled study and will randomize up to 340 patients at 55 centers in the U.S., Japan, Europe, Australia and Canada. Patients will be followed out to three years. Primary safety endpoints will include major adverse events at one month and new renal artery stenosis at six months. The pri...
Source: MDDI - November 8, 2018 Category: Medical Devices Authors: Omar Ford Tags: Business Source Type: news
FDA approves Medtronic renal denervation trial in on-med patients
Medtronic (NYSE:MDT) said today that the FDA approved a clinical trial of its Symplicity Spyral renal denervation device in patients who already take medication for their high blood pressure.
Fridley, Minn.-based Medtronic said the three-year, 340-patient Spyral HTN-On Med sham-controlled study is designed to compare treatment with the Symplicity Spyral device and a sham procedure, randomized on a 2:1 basis, after treatment with up to three anti-hypertensive medications, including diuretics, calcium channel blockers, ACE/ARB inhibitors and beta blockers. The primary safety endpoints include major adverse events at one mo...
Source: Mass Device - November 8, 2018 Category: Medical Devices Authors: Brad Perriello Tags: Clinical Trials Featured Vascular Hypertension Medtronic Renal Source Type: news
In response to the letter to the editor: Beta blockers therapy in traumatic brain injury: is it the time to disclose the brain-cardiac interactions? - Ley EJ, Dhillon NK, Barmparas G.
[Abstract unavailable]
Language: en... (Source: SafetyLit)
Source: SafetyLit - November 2, 2018 Category: International Medicine & Public Health Tags: Alcohol and Other Drugs Source Type: news
Adulterated Supplements; Fatty Acids and Aging: It's PodMed Double T! (with audio)
(MedPage Today) -- This week ' s topics also include include cardiovascular benefits from bariatric surgery and beta blockers in pregnancy (Source: MedPage Today Public Health)
Source: MedPage Today Public Health - October 20, 2018 Category: American Health Source Type: news
Day of discharge does not influence heart surgery patient readmission rates, study finds
FINDINGSA study has found that the day of the week that a patient is discharged from the hospital does not affect the likelihood that he or she will be readmitted. The study showed comparable readmission rates for weekday and weekend or holiday discharge. It has been speculated that patients who are discharged on a weekend or holiday, when staff levels are typically lower, might be more likely to be readmitted to the hospital.The researchers found that the use before surgery of beta-blockers, a type of medication used to treat heart conditions; tobacco use; and surgical site infections were independent predictors of readmi...
Source: UCLA Newsroom: Health Sciences - October 17, 2018 Category: Universities & Medical Training Source Type: news
Beta-Blockers Carry Little Risk of Cardiac Birth Defects
(MedPage Today) -- Analysis excludes large relative, absolute risk of major malformations (Source: MedPage Today Cardiovascular)
Source: MedPage Today Cardiovascular - October 16, 2018 Category: Cardiology Source Type: news
Hypertension medications ARE safe during pregnancy, study reveals
A new study from Brigham and Women's Hospital and Harvard Medical School has found that less than one percent of babies born to women who take beta-blockers have congenital malformations. (Source: the Mail online | Health)
Source: the Mail online | Health - October 15, 2018 Category: Consumer Health News Source Type: news
What Causes Hyperkalemia?
Discussion
Potassium (K+) is an alkali metal (Group 1 of periodic table with Hydrogen, Lithium and Sodium) with an anatomic number of 19. Its chemical symbol K, comes from the medieval Latin, kalium which means potash (mainly potassium carbonate or potassium hydroxide), the substance it was first isolated from.
Potassium is an important cation and it mainly resides in the intracellular fluid with only a small amount in the extracellular fluid. Potassium regulates cell volume, pH and enzyme functions. Hyperkalemia is defined as a potassium level > 5.5 mEq/L in children and > 6.0 mEq/L in newborns.
Hyperkalemia inc...
Source: PediatricEducation.org - September 24, 2018 Category: Pediatrics Authors: pediatriceducationmin Tags: Uncategorized Source Type: news
